Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409526 · ClinicalTrials.gov registry record · Phase 4
Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.
A Phase 4 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00409526 is a Phase 4 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT00409526, a Phase 4 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.
Interventions
- DRUG Inhaled Iloprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409526
The ClinicalTrials.gov registry entry for NCT00409526 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Iloprost is the first listed.
NCT00409526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409526 about?
NCT00409526 is a clinical study titled "Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.". Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.
What is the current status of trial NCT00409526?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00409526?
The interventions under investigation include: Inhaled Iloprost (DRUG).
Who is sponsoring clinical trial NCT00409526?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.